Does hyperbaric oxygen therapy (HBOT) help autism?

When tested carefully against a fair comparison, HBOT doesn’t outperform a sham treatment — and a course costs thousands of dollars.

Research synthesisUpdated 2026-08-275 sources includedProtocol v4.5 (Amdt. v4.6)

Podcast·Two-voice deep dive

Listen to the discussion

0:00
Chapters & transcript

This is an AI-generated discussion of this article, transcribed automatically. The written summary below is the reviewed source — if the two differ, go by the summary.

0:00

What is this discussion about?

Host A Imagine spending like $18,000 to put your child inside a pressurized sealed steel tube for 40 hours.

Host B Oh, wow. Yeah, that is a massive commitment.

Host A Right. All based on the promise of a medical miracle. I mean, you disrupt your life, you pull from your savings, and you just sit in a clinic day after day.

Host B Just watching your child breathe concentrated oxygen, waiting for a breakthrough.

Host A Exactly. So today we are doing a deep dive into hyperbaric oxygen therapy, or HBOT, and its relationship to autism.

Host B It's a huge topic.

Host A It really is. The core question we're exploring for you today is whether pumping a neurodivergent child full of pressurized oxygen actually improves their core symptoms. Or, you know, our family's just paying a premium for very expensive air.

Host B And it is a question that carries immense emotional weight and obviously financial weight.

Host A Oh, totally.

Host B Because the claims you find online, they are incredibly persuasive. They often wrap themselves in this language of cutting edge neuroscience.

Host A Yeah, it sounds very official.

Host B Right. And when you're a parent navigating the incredibly murky diagnostic waters of neurodevelopment, that kind of concrete machine driven promise, It just feels like a lifeline.

Host A Which is exactly why we need to cut through the noise for you. Okay, let's unpack this.

1:16

What's the theory behind using oxygen therapy for autism?

Host A To get you the real answers, we are looking at a stack of rigorous sources today.

Host B Lots of data to get through.

Host A Yep. We're pulling from a comprehensive spectrum Connect Audit Document and Findings Report, a 2024 Harvard Health Review, FDA Consumer Updates, and crucially, multiple randomized controlled trials.

Host B Which are the gold standard, yeah.

Host A Exactly. We want to find out what the medical evidence actually proves so you can be fully informed when you see these treatments advertised, because the claims range from like miracle cure to unproven risk.

Host B The contrast in the source material is honestly jarring. On one hand, you have these clinics marketing this as a revolutionary intervention.

Host A Right.

Host B But then on the other, the FDA and major medical reviews are waving these massive red warning flags.

Host A So to understand how the gap between those two viewpoints got so wide, I feel like we first have to understand the mechanical theory being sold to these families without getting bogged down in medical jargon.

Host B Let's start there. So hyperbaric oxygen therapy itself, it isn't pseudoscience. It is a legitimate FDA cleared medical treatment. Patients go into a sealed chamber and they breathe pure oxygen at a pressure higher than normal atmospheric pressure.

Host A So it's essentially like going deep underwater.

Host B Yeah, exactly. Like scuba diving. And it's used for decompression sickness, what divers call the bends.

Host A Oh, right. Sure.

Host B It also treats carbon monoxide poisoning and it helps heal severe diabetic foot ulcers by basically forcing oxygen into damaged tissues.

Host A Okay, but it's absolutely not FDA approved for autism.

Host B No, not at all. The leap from treating a physical wound to treating a complex neurodevelopmental condition relies on a very specific hypothesis.

Host A Okay, what's the theory?

Host B Well, the proponents of HBOT for autism argue that some autistic individuals suffer from neuroinflammation and something called a cerebral hypoperfusion.

Host A Cerebral hypoperfusion.

Host B Right. Which is really just a medical way of saying a lack of adequate blood flow to certain areas of the brain.

Host A OK. So the theory is basically that the brain is a sponge that has like dried out in certain spots.

Host B That's a good way to picture it.

Host A And by pressurizing the whole physiological system you are forcing oxygen rich blood into those dormant pockets to kind of bring them back online.

Host B That is the exact mechanical promise they're making. And, you know, you can see why it appeals to people.

Host A I mean, it sounds super logical.

Host B It does. It sounds like engineering. You have a physical problem, which is a lack of oxygen, and a physical solution, a pressurized oxygen tank.

3:46

What did the original 2009 study claim?

Host A And it wasn't just hypothetical marketing either.

Host B Yeah.

Host A The sources show there was actual research that seemed to validate this, right?

Host B Yes, early on.

Host A We have to talk about that headline-making trial from 2009 by Rosignol and colleagues because this is the study you see plastered all over the promotional brochures for these clinics.

Host B It's everywhere.

Host A They reported a massive 80% improvement in autism symptoms in the HBOT group. And that was compared to just 38% in the control group.

Host B Yeah.

Host A When you hear 80% improvement in a clinical trial, well, it feels like case closed.

Host B Right, until you actually look at the methodology.

Host A Okay, what was the catch?

Host B Well, major clinical reviews define hyperbaric oxygen therapy very strictly. To trigger the physiological changes we just talked about, the therapy requires an atmospheric pressure, which we abbreviate as ATA of greater than 1.4.

Host A Okay, 1.4 ATA.

Host B Right. And the patient must be breathing 100% pure oxygen.

Host A But the RAS signal trial didn't do that, did they?

Host B No, they did not. They used a protocol they called mild HBOT. Mild. Yeah. They set the pressure to just 1.3 ATA, and the oxygen concentration was only 24%. Wow.

Host A Okay, just to put that in perspective for you, the normal air we breathe every day is about 21% oxygen at 1 ATA.

Host B Exactly. They essentially bumped the oxygen up by a tiny fraction and slightly pressurized the room.

Host A That hardly seems like hyperbaric therapy.

Host B It really isn't. The 2024 Harvard Health Review and other systematic audits were so critical of this that some actually excluded the study entirely.

Host A Wow, just threw it out.

Host B Yeah, because it didn't even meet the basic clinical definition of the therapy it claimed to be testing.

Host A And beyond the oxygen levels, the way they measured that 80% improvement was heavily flawed too, right?

Host B Very flawed.

Host A They relied on something called the ATEC, the Autism Treatment Evaluation Checklist. And the source literature notes this is an unvalidated measurement tool.

Host B Right. It's highly subjective.

Host A Yeah. So when a trial leans on a tool that hasn't been clinically proven to measure what it claims to measure, any positive signal it generates is inherently weak.

Host B Absolutely. Plus, you have to consider that the researchers involved were a proponent group.

Host A Meaning they had a known prior interest in the therapy actually succeeding.

Host B Exactly. But science, you know, it relies on replication. When a study makes a claim that bold, independent researchers will step in to verify it using stricter controls.

6:10

What happened when rigorous, sham-controlled trials tested this?

Host B Which leads us to the follow-up studies. Specifically, Grampesha in 2010 and a remarkably rigorous double-blind trial by Sam Penthevivat in 2012.

Host A The Sampath Eviavat study is fascinating because they tested 60 children in Thailand at a much higher legitimate pressure of 1.5 ATA.

Host B Yes, real hyperbaric pressure.

Host A But the absolute genius of these follow-up studies is how they engineered the control group because they didn't just have one group sit in a tank and another group sit in a waiting room.

Host B No, they built a highly convincing fake experience. It's the logistical marvel of a proper sham trial. If you want to know if the oxygen is actually changing the brain, you have to completely isolate the oxygen from the experience of receiving the treatment.

Host A So wait, the children in the control group went into the exact same impressive high-tech hyperbaric chamber.

Host B The exact same one.

Host A The machine hummed loudly, the doors locked heavily, and the families went through the entire intent of daily routines.

Host B Yep. The chamber was even slightly pressurized to about 1.15 ATA, just enough to make the kids' ears pop so everyone felt like they were diving.

Host A Yeah. But inside, they were basically just breathing regular room air.

Host B It was a flawless double-blind setup.

Host A Wow.

Host B The doctors didn't know who was getting the real treatment, the parents didn't know, and the kids didn't know.

Host A And the results of that 2012 trial are the linchpin of the current medical consensus because both groups improved.

Host B Both of them.

Host A Both the kids breathing the high pressure pure oxygen and the kids breathing the slightly compressed room air saw behavioral improvements. But there was absolutely no statistically significant difference between the two groups.

Host B Right. The group getting the intensive clinical grade oxygen didn't perform any better than the group breathing the fake treatment.

Host A So wait, if both groups improve, does that mean just sitting in a fancy, important-looking medical tube makes kids do better?

Host B Essentially, yes.

Host A It sounds like testing a magic wand where just waving a stick makes people happier.

Host B Yeah.

Host A Regardless of whether it actually has magic in it or it's just a twig from the backyard.

Host B That's a perfect analogy. The medical term for the magic is the placebo effect. Though in pediatric behavioral trials, we often call it the attention effect or the participation effect.

Host A Okay, that makes sense.

Host B The improvements weren't coming from the atmospheric pressure forcing oxygen into the brain. They were coming from the structured environment, the daily routine, the focused time with caregivers, and just the sheer psychological expectation that a massive intervention was taking place.

8:39

Why did parents and clinicians see completely different results?

Host A Which brings us to the most revealing part of the data. Because if the oxygen isn't doing anything, who is actually looking at these kids and deciding they are improving?

Host B This is where it gets really fascinating.

Host A Yeah, the 2012 TIE study uncovered a massive, almost unbelievable contradiction between what the parents perceived and what the trained clinicians observed.

Host B The observer effect in these trials is incredibly telling. The Sampantha-Vivat study used multiple standardized rating scales. One of them was the Clinical Global Impression of Severity, or CGIS. This is a tool designed to measure how severe a patient's symptoms appear at a specific moment in time on this scale. The parents rated a highly significant improvement in their children. The p-value was .005.

Host A And just to clarify, a p-value of .005 is a statistical way of saying we are overwhelmingly confident that we saw a real tangible change.

Host B Exactly. The parents were absolutely convinced their kids were doing significantly better.

Host A But when the clinicians used that exact same CGIS scale to evaluate the children, they saw no such thing, right?

Host B Nothing. Their p-value is 0.10, which means the results were not statistically significant. The doctors observed no meaningful change in the severity of the symptoms.

Host A And then, on a completely different scale, the clinical global impression of change, which measures how much a patient has altered over time, the exact opposite happened. Yes. The clinicians noted a statistically significant change with a p-value of 0.03, while the parents completely missed it, scoring a non-significant 0.28.

Host B It's wild. They were looking at the exact same children and seeing entirely different realities.

Host A So this contradiction really strikes the heart of why autism research is so notoriously difficult.

10:24

Isn't a parent's read on their own kid the most reliable one?

Host A But here is where I have to push back a bit on behalf of the parents listening.

Host B OK, sure.

Host A If a child is acting better at home, shouldn't the parents rating count more? I mean, a clinician only sees a child for a brief, highly structured appointment in a sterile office environment.

Host B Right.

Host A The parents live with the child 24 hours a day, seven days a week. They see the meltdowns, the sleep patterns, the subtle shifts in eye contact.

Host B It is a completely valid argument. Parents absolutely possess the most comprehensive, nuanced view of their child's day-to-day existence. No clinician can replicate that context. However, that intense proximity is also exactly why subjective reporting is so vulnerable to expectation bias. And it's why double-blind, sham-controlled trials are the bedrock of medical science.

Host A We're talking about the psychology of investment here, aren't we?

Host B Exactly. Consider the reality of a family undergoing this protocol. They are investing immense hope. They're disrupting their entire family dynamic to drive to a clinic, put their child in a chamber and wait.

Host A Yeah.

Host B And they are spending thousands of dollars. When you have that much emotional and financial skin in the game, your brain is psychologically primed to seek out a return on that investment.

Host A You want it to work so desperately that you subconsciously analyze every tiny interaction. Like, a child might have a naturally calm afternoon, which, you know, happens occasionally anyway, but now the parent attributes that calm afternoon to the chamber.

Host B Exactly. You magnify the positives and you minimize the baseline.

Host A That makes total sense.

Host B The clinicians conversely lack the rich home context, but they also lack the emotional sunk cost. They are trained to objectively measure specific diagnostic criteria.

Host A Right.

Host B So when parent ratings and clinician ratings wildly diverge in a blinded study, it is a massive indicator that the perceived improvements are driven by subjective human hope and environmental structure, not a neurochemical change driven by oxygen therapy.

12:18

What's the actual cost of trying this anyway?

Host A So the clinical evidence points firmly to a lack of efficacy. The oxygen is not the magic ingredient.

Host B It's not.

Host A But I can easily hear a parent out there thinking, okay, the oxygen doesn't change the brain. But both groups kind of improved anyway, just from the routine and the extra attention. If my child gets a little better, even if it's just a placebo effect, what is the harm in trying?

Host B Well, we have to evaluate the true cost of a null result.

Host A Okay.

Host B Because the harm here is profound, even if it isn't immediately visible. From a purely physical standpoint, the sources confirm that HBOT administered at an accredited facility is generally well tolerated.

Host A Though there are still physical risks involved, right? I mean, we are talking about highly compressed environments.

Host B There are. There is a small but real chance of middle ear barotrauma. Ouch. Yeah. It's similar to the pain of your ears failing to pop on an airplane, but potentially much more severe.

Host A Right.

Host B There are rare instances of oxygen toxicity resulting in seizures. And because the chamber is flooded with concentrated oxygen, there is an extreme fire risk if the facility isn't strictly following safety protocols. Wow. OK.

Host A But broadly speaking, the physical danger is relatively low. The devastating harm is indirect.

Host B It's the financial reality and the opportunity cost.

Host A Let's break down the economics from the audit document. Because HPOT is an unapproved, off-label treatment for autism, insurance companies will not cover it.

Host B Right, so families are paying entirely out of pocket.

Host A Entirely. A single session costs between $250 to $450.

Host B And the protocols require heavy repetition. You don't just go for one afternoon. A typical course demands 20 to 40 sessions.

Host A Right.

Host B If we do the math on a 40-session protocol at $450 a pop, that is $18,000.

Host A For one single course.

Host B Of a treatment that rigorous sham trials have proven works no better than sitting in a normal room.

Host A It is a staggering amount of money. And this feeds directly into the FDA's most urgent warning regarding unproven therapies, which is opportunity cost.

Host B Yes.

Host A Every hour spent inside that hyperbaric chamber is an hour not spent in proven evidence based therapies. So it's essentially like buying a thousand dollar lottery ticket when you really need to be paying your rent. The physical paper of the lottery ticket won't hurt you. The danger is what you are not doing with those vital resources.

Host B Exactly.

Host A Every afternoon spent commuting to a clinic to sit in the tank is an afternoon arrest. A child isn't receiving applied behavior analysis, speech therapy, or occupational therapy. You're draining the bank account and running down the clock during crucial developmental windows on a treatment that the gold standard science says does not work.

Host B It places families in a heartbreaking position. They are doing everything in their power to help their child. But their resources are being siphoned away by a regulatory gray area.

15:11

What happened with the FDA's warning page?

Host A Which brings us to a recent highly confusing event in the regulatory landscape. Because if a parent is trying to do their due diligence today, they might stumble across a piece of breaking news from our sources that seems to completely contradict everything we just discussed.

Host B Ah, yes. The FDA website update.

Host A Right, in January, 2026, Disability Scoop reported that the FDA suddenly pulled down a specific consumer update webpage.

Host B The page was titled, Hyperbaric Oxygen Therapy, Don't Be Misled. And it was their primary public warning, explicitly stating that HBOT is unproven for autism.

Host A And then it just vanished from the internet. Just gone. If you're a desperate parent and you see that the federal government suddenly deleted their major warning label against this therapy, the immediate logical conclusion is they must have found new evidence. A new trial must have proven that it works after all.

Host B And that highlights how easily administrative actions can be misinterpreted as evidentiary medical findings. Right. We have to clarify this distinction. The FDA withdrew the page strictly for administrative reasons.

Host A Because government websites undergo departmental reorganizations, formatting updates, and mass archiving all the time.

Host B Exactly. Researchers quoted in the news coverage were absolutely adamant in clarifying the situation. The underlying medical consensus has not shifted a single inch.

Host A Okay, that's crucial.

Host B There are no secret new trials showing that HBOT cures autism. An administrative sunsetting of a specific URL does not alter the scientific trial data.

Host A So what does this all mean? It's like if a library accidentally deletes the digital catalog record for a history book.

Host B Perfect analogy.

Host A The physical book didn't disappear, and the history written inside it certainly didn't change just because the website updated. The facts remain the facts, even if the warning label temporarily falls off the shelf.

Host B A missing web page does not equal an evidence change. The rigorous sham-controlled trials still show a null result. The opportunity cost remains massive. None of that changes because of a dead hyperlink.

17:10

What's the bottom line?

Host A This has been an incredibly eye-opening journey through the data. We started with the initial promise, an early, methodologically weak study that sparked widespread hope by claiming massive improvements. But it used an unvalidated measurement tool in oxygen levels that barely qualified as hyperbaric.

Host B Right. And then we explored the gold standard science. Rigorous, double-blind trials utilizing perfectly engineered fake chambers proved that the pressurized oxygen offers no meaningful benefit over a placebo for core autism symptoms.

Host A The improvements families sometimes see aren't driven by neurochemical changes. They are driven by the structured routine, the focused attention, and the powerful psychology of expectation bias.

Host B Exactly.

Host A And while the therapy is mostly physically safe at accredited clinics, it carries a devastating financial burden, running into the tens of thousands of dollars while actively pulling children away from proven, evidence-based care.

Host B And finally, we saw how crucial it is to separate administrative government website updates from actual medical breakthroughs. The science remains absolutely clear.

Host A Navigating this kind of research, parsing through p-values and sham trial methodologies, it's incredibly tough for anyone outside the medical field. And that is exactly why we want to share a specific message with you today.

Host B Yes, please do.

Host A Currently, Spectrum Connect is bridging the science of autism therapies to make it more approachable for parents. If you are a credentialed expert, an MD, PhD, PsyD, or DO, and would like to help us in validating our findings, email us at research at spectrumconnect.us. Let me repeat that if you are a credentialed expert who wants to help validate this kind of research, email research at spectrumconnect.us.

Host B Synthesizing all of this data leaves me with one incredibly compelling, lingering thought for everyone to mull over.

Host A What's that?

Host B Well, we spent a lot of time analyzing the sheer power of the sham effect. The realization that merely participating in a highly structured, attentive, entirely fake treatment is powerful enough to make both parents and children perceive real behavioral improvements.

Host A It just proves how deeply sensitive human beings are to routine and dedicated attention.

Host B It does. And it raises a massive challenge for the scientific community. How can we ethically harness that?

Host A Oh, wow. Yeah.

Host B If the expectation of care and the structure of a daily routine yield tangible psychological benefits, how can we engineer those exact elements into proven, low-cost daily therapies? How do we capture the sheer power of expectation without asking families to step inside a $20,000 pressurized tank?

Host A That is the ultimate goal. Because when you're standing in those murky diagnostic waters and the traditional x-ray machine of neurodevelopment simply cannot give you a clean answer, you do not need an overpriced placebo. You need a real compass. Thanks for joining us on this deep dive into the data. We will catch you next time.

Hyperbaric Oxygen Therapy (HBOT) Not supported — no benefit over sham

Key Takeaways

The careful evidence says no — in properly sham-controlled trials, children who got real HBOT did no better than children who got a fake treatment. Both groups improved a little, a sign the change came from attention and expectation, not oxygen.

The one positive study had a big weakness — it used a weaker “mild” HBOT setup and comes from a research group with a proponent interest in the treatment. Independent, properly sham-controlled trials didn’t repeat its result.

It’s generally physically safe at an accredited facility — possible side effects are usually minor, like ear or sinus discomfort. Serious events are rare. Chambers do carry a fire risk, so the setting matters.

The real cost is money and time, not injury — a course runs into the thousands of dollars, insurance won’t cover it for autism, and it’s not FDA-approved for this use. The bigger risk is spending both here instead of on care that’s proven to help.

A warning page being taken down isn’t new evidence — a federal warning page listing HBOT among unproven autism therapies was recently removed. That was an administrative change, not a new study showing it works.

What this means for you

Hyperbaric oxygen therapy (HBOT) means sitting in a pressurized chamber breathing oxygen. It’s a real, FDA-approved treatment for certain medical problems — like decompression sickness and some serious wounds — but it is not FDA-approved for autism, and that’s the question here. One early study looked promising. But when researchers ran the fair test — comparing real HBOT against a “sham” chamber, so no one knew who got the real thing — children who got real HBOT did not do any better than children who got the fake. In those careful studies, children in both groups improved a little, which is a sign the improvement came from attention and expectation, not from the oxygen itself.

This is a studied-and-refuted finding, not a too-little-research one: there are randomized trials, and when they’re properly controlled, they’re null. The one positive study used a weaker “mild HBOT” setup that some reviews say doesn’t even meet the accepted definition of HBOT, and it comes from a research group with a proponent interest in the treatment — independent, properly sham-controlled trials did not repeat its result. At an accredited facility, the procedure itself is generally physically safe; the bigger risk here is financial and practical — a course runs into the thousands of dollars, insurance won’t cover it for autism, and the time and money may be better spent on approaches with stronger support.

When tested against a fair comparison, HBOT doesn’t outperform a sham treatment for autism symptoms — the direct physical risk is low, but the cost is real, and so is the risk of spending time on this instead of care that’s proven to help.

A regulatory change isn’t a new study. A federal warning page listing HBOT among unproven autism therapies was recently taken down. Reporting at the time indicated this was an administrative change, not the result of new evidence — the trial evidence hasn’t changed.

Where the studies landed

Not supported — no benefit over sham

The apparent controversy here is largely an artifact: the one positive result rests on a weaker, ambiguous sham and a research group with a stake in the outcome. The two independent, properly sham-controlled trials agree: no real benefit.

1 The outlier, and why it doesn’t hold up

4 No benefit over a fair comparison

Tap the cover to open it.
One studyReview of many studies

Tap any tile to read it.

The outlier, and why it doesn’t hold up1
One double-blind trial reported a striking positive result — but it used a weaker “mild” HBOT setup some reviews say falls outside the accepted definition, sham adequacy is debated, and it comes from a proponent-affiliated research group. It has not been independently replicated.
No benefit over a fair comparison4
Two independent, properly sham-controlled trials and the reviews that survey this literature all agree: HBOT does not outperform a sham. Both trial arms tend to improve similarly — the signature of attention and expectation, not a real treatment effect.

Spectrum Connect reviews published research on interventions parents are exploring for their autistic children — so you can see where the evidence actually stands. No agenda, no selling, no cherry-picking. Just the studies, our method, and what it means for you.

See the research behind this For anyone who wants to check our work · 5 sources
01

Where we looked

This run was a scoping search only — done via general web search (2 searches: one for trial/effectiveness literature, one for regulatory, safety, and critique literature), not the reproducible Boolean search of record and not the PubMed/Epistemonikos API layer we use on a fully conformant run. That means we can’t publish reproducible per-database counts or a formal PRISMA flow for this run. Below is the search string a full conformant pass would run against PubMed, Embase, PsycINFO, the Cochrane Library, Web of Science, Epistemonikos, and the Randomised Controlled Trials in Hyperbaric Medicine register — we haven’t executed it against the database APIs yet.

(autism OR autistic OR ASD OR "autism spectrum") AND ("hyperbaric oxygen" OR HBOT OR HBO2 OR "hyperbaric chamber") AND (random* OR sham OR placebo OR trial OR "systematic review") Run on PubMed →
02

What we did with what we found

≈16records surfaced by 2 web searches
n/ano formal screen run; RCTs & review hand-selected; uncontrolled precursor studies set aside
5hand-selected (1 systematic review + 3 core RCTs + 1 retrospective/review analysis)
03

What the strongest evidence says

Core autism symptoms vs. sham

The two adequately sham-controlled trials agree: HBOT doesn’t outperform a fake treatment. Both groups tend to improve a little — a sign of attention and expectation, not oxygen.

How sure
Moderate
Physical safety

Generally safe and well tolerated at an accredited facility; minor issues like ear or sinus discomfort are the most common. Serious events are rare, but chambers carry a fire risk.

How sure
Moderate
Financial & opportunity cost

A course costs thousands of dollars and isn’t covered by insurance for autism. The FDA’s own stated concern is that families may spend time and money here instead of on proven care.

How sure
Documented
Ray Kawai · Protocol v4.5 BCAT · Open record
Spectrum Connect is not a medical provider, and nothing here is medical advice. This page shows where the research stands and how we got there. It is not a recommendation, and it is not a substitute for your child’s doctor or care team. What you do with it is yours to decide, together with them.

What would you like to do?

Want to talk to a parent who’s been there?

We match you with families whose kid is like yours. Free, takes two minutes.

Join Free
Heard of something we haven’t covered?Suggest an article

If another parent, a clinic or a video mentioned a therapy you can’t find here, tell us. We’ll read the research and review it next.

Suggest an article
Think we got something wrong?Report a factual error

We publish the whole record so it can be checked, and that only counts if we act on what you find. If a number looks wrong, a study is missing or has been retracted, or we’ve read a finding in a way the evidence doesn’t support, tell us.

You don’t need a research background to file one. “This doesn’t match what our doctor told us” is a useful report. Every one reaches a person: we reply within seven days, and within thirty we have either corrected the page or told you when we will. Substantive reports send the affected steps back through the protocol and need fresh sign-off before anything here changes.

Report a factual error
Are you a clinician or researcher?Review this article

If you have read this and the evidence holds up, you can sign off on it. We send you a personal review link where you confirm your credentials, and our team checks every review before anything is published. Once approved, your name and a link to your profile appear on this article.

Ask to review this